Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

In vitro/In vivo Correlation of Sustained Release Diltiazem

딜티아젬서방정을 이용한 In vitro/In vivo 상관성

  • Published : 2002.12.20
Download PDF
⟨ Previous Next ⟩

Abstract

IVIVC (In vitro/in vivo correlation) is useful for predicting in vivo results from in vitro data. The aim of this study was to develop IVIVC of sustained release diltiazem. For this purpose, three types of diltiazem tablets with different in vitro dissolution rates were prepared. An in vitro dissolution testing method comprising of paddle apparatus, 50 rpm, water as dissolution medium was developed. Under these condition, we demonstrated that AUCinf could be predicted by evaluating $d_{70%}$ (time dissolved 70%) in vitro since the in vivo AUCinf was correlated with the in vitro $d_{70%}$ (r=-0.9981).

Keywords

References

  1. M. Zahirul I. Khan, Dissolution testing for sustained or controlled release oral dosage forms and correlation with in vivo data : challenges and opportunities, Int. J. Pharm., 140, 131-143 (1996) https://doi.org/10.1016/0378-5173(96)04561-9
  2. Venkata ramana S. Uppoor M. Pharm., Ph. D., R. Ph., Regularoty perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations, J. Controlled release, 72, 127-132 (2001) https://doi.org/10.1016/S0168-3659(01)00268-1
  3. B. Sreenivasa Rao, A. seshasayana, S. V. Pardha saradhi, N. Ravi Kumar, Cheruvu P. S. narayan, K. V. Ramana Murthy, Correlation of in vitro release and in vivo absorption characteristics of rifampicin from ethylcellulose coated nonpareil beads, Int. J. Pharma., 230, 1-9 (2001) https://doi.org/10.1016/S0378-5173(01)00835-3
  4. Skelley, J. P., Amidon, G. L., Barr, W. J., Benet, L. Z., Carter, J. E., Robinson, J. R., Shah, V. P., Yacobi, A., Report of the workshop on in-vitro in-vivo testing and correlation for oral controlled modified-release dosage forms. J. Pharm. Sci., 79, 849-854 (1990) https://doi.org/10.1002/jps.2600790923
  5. Aristides Dokoumetzidis and Panos Macheras, A population growth models of dissolution, Pharm. Res., 14(9), 1122-1126 (1997) https://doi.org/10.1023/A:1012182102257
  6. Robert E. Wiens, Dennis J. Runser, Joseph P. Lacz, and Dan C. Dimmitt, Quantitation of diltiazem and desacetyldiltiazem in dog plasma by high-performance liquid chromatography, J. Pharm. Sci., 73(5), 688-689 (1984) https://doi.org/10.1002/jps.2600730525
  7. Nattee Sirisuth and Natalie D. Eddington, In-vitro-in vivo correlation definitions and regulatory guidance, Int. J. Generic drugs, ISSN 0793 758X US/canada
  8. Nattee sirisuth and Natalie D. Eddington, Vitro-in vivo correlations, Int. J. Generic drugs, 250-258, ISSN 0793 694X-US/Canada
  9. Gordon L. Amidon, Hans Lennernas, Vinod P. Shah, and John R. Crison, A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res., 12(3), 413-420 (1995) https://doi.org/10.1023/A:1016212804288
  10. FDA Guidance for industry: Immediate release solid dosage forms; scale-up and post approval changes (SUPAC-IR); chemistry, manufacturing and controls, in vitro dissolution testing and in vivo bioequivalence documentation, November, 1995
  11. FDA Guidance for industry: modified release solid oral dosage forms; scale-up and post approval changes (SUPAC-MR); chemistry, manufacturing and controls; in vitro dissolution testing and in vivo bioequivalence documentation, september, 1997a
  12. FDA Guidance for industry: Extended release oral dosage forms; development, evaluation and application of in vitro/in vivo correlation, september, 1997b
  13. FDA Guidance for industry: Dissolution testing of immediate release solid oral dosage forms, August, 1997c
  14. Vinod P. Shah, Yi Tsong, Pradeep Sathe, and Jea-Pei Liu, in vitro dissolution profile comparison-statistics and analysis of the similarity factor,$f_2$ , Pharm. Res., 15(6), 1998
  15. Bee-Hwan Chung and Chang-Koo Shim, Dissolution of theophylline from sustained-release dosage forms and correlation with saliva bioavailability parameters, J. Pharm. Sci., 76(10), 784-787 (1987) https://doi.org/10.1002/jps.2600761006
  16. P. Costa, An alternative method to the evaluation of similarity factor in dissolution testing, Int. J. Pharm., 220, 77-83 (2001) https://doi.org/10.1016/S0378-5173(01)00651-2
  17. G. Bianchetti, M. Regazzi, M. Rondanelli, V. Ascalone, M. Morselli, Bioavailability of diltiazem as a function of the administered dose., Biopharm. Drug Disp., 12, 391-401 (1991) https://doi.org/10.1002/bdd.2510120508
  18. E. U. Kolle, H. R. Ochs, K. O. Vollmer, Pharmacokinetic model of diltiazem. Arzneim. Forsch./Drug Res., 33, 972-977 (1983)
  19. Ph. Herman, S. D. Rodger, G. Remones, J. P. Thenot, D. R. London, P. L. Morselli, Pharmacokinetics of diltiazem after intravenous and oral administration. Eur. J. Clin. Pharmacol., 24, 349-352 (1983) https://doi.org/10.1007/BF00610053